share_log

Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

Milestone Pharmicals将出席第23届年度Needham医疗保健会议
GlobeNewswire ·  04/03 08:00

MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company presentation at the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024 at 8:45 am ET.

蒙特利尔和北卡罗来纳州夏洛特,2024年4月3日(GLOBE NEWSWIRE)——里程碑制药公司(纳斯达克股票代码:MIST)今天宣布,其管理团队成员将在美国东部时间2024年4月10日上午8点45分举行的第23届Needham年度虚拟医疗会议上发表公司演讲。

The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone's website.

在Milestone网站的 “新闻与活动” 部分进行演示后,可以在大约90天内观看网络直播和重播。

About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company's focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat highly symptomatic episodic attacks associated with PSVT and AFib-RVR.

关于里程碑制药
Milestone Pharmicals Inc.(纳斯达克股票代码:MIST)是一家生物制药公司,正在开发和商业化创新的心血管解决方案,以改善患有复杂和改变生活的心脏病患者的生活。该公司专注于了解未满足的患者需求和改善患者体验,这促使我们开发了新的治疗方法,让患者在自我管理护理方面发挥积极作用。Milestone的主要研究产品是etripamil,这是一种新型的钙通道阻滞剂鼻腔喷雾剂,正在研究患者无需医疗监督即可自行服用,以治疗与PSVT和AFIB-RVR相关的高症状发作性发作。

Contact:
Kim Fox, Vice President, Communications, kfox@milestonepharma.com

联系人:
金·福克斯,传播副总裁,kfox@milestonepharma.com

Investor Relations
Chris Calabrese, ccalabrese@lifesciadvisors.com
Kevin Gardner, kgardner@lifesciadvisors.com

投资者关系
克里斯·卡拉布雷斯,ccalabrese@lifesciadvisors.com
凯文·加德纳,kgardner@lifesciadvisors.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发